Abstract:Ubiquitin specific peptidase 2a (USP2a) plays critical roles in protein degradation and other cellular activities. Currently, our understanding on USP2a dysregulation in subjects with hepatocellular carcinoma (HCC) and its roles in HCC pathogenesis is limited. In this study, we found that USP2a mRNA and protein levels were significantly upregulated in HCC tumors from both human and mice. USP2a overexpression in HepG2 and Huh 7 cells significantly increased cell proliferation while inhibition of USP2a activity by chemical inhibitor or stable knockout of USP2 by CRISPR markedly reduced cell proliferation. In addition, USP2a overexpression significantly augmented the resistance while knockout of USP2a markedly increased the susceptibility of HepG2 cells to bile acid-induced apoptosis and necrosis. Consistent with the oncogenic activities detected in vitro, overexpression of USP2a promoted de novo HCC development in mice with significantly increased tumor occurrence rates, tumor sizes and liver/body ratios. Further investigations with unbiased co-immunoprecipitation (Co-IP)-coupled proteomic analysis and Western blot identified novel USP2a target proteins involved in cell proliferation, apoptosis, and tumorigenesis. Analysis of those USP2a target proteins revealed that USP2a's oncogenic activities are mediated through multiple pathways, including modulating protein folding and assembling through regulating protein chaperones/co-chaperones HSPA1A, DNAJA1 and TCP1, promoting DNA replication and transcription through regulating RUVBL1, PCNA and TARDBP, and altering mitochondrial apoptotic pathway through regulating VDAC2. Indeed, those newly identified USP2a target proteins were markedly dysregulated in HCC tumors. In summary, USP2a was upregulated in HCC subjects and acted as an oncogene in the pathogenesis of HCC through multiple downstream pathways. The findings provided molecular and pathogenesis bases for developing interventions to treat HCC by targeting USP2a or its downstream pathways.

The Molecular Mechanisms of Regulation on USP2's Alternative Splicing and the Significance of Its Products.

Ubiquitin-specific peptidase 22 in cancer

Ubiquitin Specific Protease 2: Structure% Isoforms% Cellular Function% Related Diseases and Its Inhibitors

Characterization of alternatively spliced products and tissue-specific isoforms of USP28 and USP25

Dysregulation and Activities of Ubiquitin Specific Peptidase 2b in the Pathogenesis of Hepatocellular Carcinoma

USP39 Promotes Hepatocellular Carcinogenesis Through Regulating Alternative Splicing in Cooperation with SRSF6/HNRNPC

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

Opposing USP19 Splice Variants in TGF-β Signaling and TGF-β-induced Epithelial–mesenchymal Transition of Breast Cancer Cells

Dysregulation and oncogenic activities of ubiquitin specific peptidase 2a in the pathogenesis of hepatocellular carcinoma

The Dual Role of USP11 in Cancer

USP15 in Cancer and Other Diseases: From Diverse Functionsto Therapeutic Targets

USP2 is an SKP2 Deubiquitylase That Stabilizes Both SKP2 and Its Substrates

USP3: Key deubiquitylation enzyme in human diseases

USP5: Comprehensive insights into structure, function, biological and disease-related implications, and emerging therapeutic opportunities

USP14: Structure, Function, and Target Inhibition

Mechanism of Alternative Splicing and Its Regulation.

Spotlight on USP4: Structure, Function, and Regulation

Alternative Pre-mRNA Splicing, Cell Death, and Cancer.

USP 2 a negatively regulates IL-1 band virus-induced NFk B activation by deubiquitinating TRAF 6

The emerging role of USP29 in cancer and other diseases

USP2a negatively regulates IL-1β- and virus-induced NF-κB activation by deubiquitinating TRAF6.